<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css"
        integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw=="
        crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Custom CSS -->
    <link rel="stylesheet" href="css/style.css">
</head>

<body>

    <div class="main_page5 position-relative fixedHeight">
        <div class="nav_orange">
            <div class="nav_orange_left">
                <h4 class="GothamBook pt-3 mb-0">MM1: Ixazomib (NINLARO) + Rd (vs placebo + Rd) was distinguished by rapid, deep, and durable response<sup>1,2</sup></h4>
            </div>
            <div class="nav_orange_right">
                <img src="img/logo_orange.png" alt="">
            </div>
        </div>
        <!-- page 5 middle box -->
            <div class="page5_middle_box page25_middle_box mt-3 mb-4" style="align-items: start;">
                <div class="page25_middle_left">
                    <h4 class="txt_orange GothamBook mt-1 mb-4">ORR WITH IXAZOMIB (NINLARO) +<br>Rd VS placebo + Rd<sup>1,2</sup></h4>
                    <img class="img-fluid w-100" src="img/page25_chart_left.png" alt="" style="max-height: 220px;">
                </div>
                <div class="page25_middle_right">
                    <h4 class="txt_orange GothamBook mt-1 mb-4">TTR WITH IXAZOMIB (NINLARO) + Rd <br>VS placebo + Rd<sup>1,2</sup></h4>
                    <img class="img-fluid" src="img/page-25-graph.jpg" alt="">
                </div>
            </div>
            <div class="page5_middle_box page25_middle_box mb-3 flex-wrap">
                <h5 class="page21_blue fs-11" style="width: 49%; font-weight: bold;">Ixazomib (NINLARO) + Rd delivered significantly deeper <br>
                    response at 14.7 months’ median follow-up vs placebo + Rd<sup>1</sup></h5>
                <h5 class="page21_blue fs-11" style="width: 49%; font-weight: bold;">Patients receiving Ixazomib (NINLARO) + Rd achieved response after <br>
                    approximately one 28-day cycle<sup>1</sup></h5>
                <p class="GothamBook dark_secondary fs-11 mt-1 mb-0" style="width: 49%;">Patients received a median of 17 (range 1–34) and 15 (range 1–34) treatment
                    cycles in the Ixazomib (NINLARO) and placebo groups, respectively<sup>2</sup></p>
            </div>
    </div>


        <!--  -->
            <div class="page5_middle_box mb-3">
                <div class="page5_btns_sm">
                    <a href="../page26/index.html" class="text-uppercase"><p class="mb-0 position-relative">REAL-WORLD EVIDENCE</p></a>
                </div>
            </div>

            <div class="page5_middle_box page5_p_sm w-75">
                <p class="GothamLight">CR = complete response; ORR = overall response rate; Rd = REVLIMID® (lenalidomide) + dexamethasone; TTR = time to response; VGPR = very good partial response.</p>
            </div>


            <div class="footer_page5">
                <div class="d-flex align-items-end">
                    <div class="page5_btns_md">
                        <a href="../page5/index.html"><p class="mb-0 position-relative">MM1 study design</p></a>
                        <a href="../page6/index.html"><p class="mb-0 position-relative">MM1 patient baseline characteristics</p></a>
                        <a href="../page8/index.html"><p class="mb-0 position-relative">RWE study Hajek et al.</p></a>
                        <a href="../page15/index.html"><p class="mb-0 position-relative">RWE study Terpos et al.</p></a>
                        <a href="../page11/index.html"><p class="mb-0 position-relative">RWE study Chari et al.</p></a>
                        <a href="../page18/index.html"><p class="mb-0 position-relative">RWE study Minarik et al.</p></a>
                        <a href="../page21/index.html"><p class="mb-0 position-relative">MM1 PFS</p></a>
                        <a href="../page23/index.html"><p class="mb-0 position-relative">MM1 PFS in patients with high-risk cytogenetics</p></a>
                        <a href="../page25/index.html"><p class="mb-0 position-relative">MM1 response rate</p></a>
                        <a href="../page28/index.html"><p class="mb-0 position-relative">MM1 PFS in <br> pre-treated patients</p></a>
                        <a href="../page31/index.html"><p class="mb-0 position-relative">MM1 safety data</p></a>
                        <a href="../page34/index.html"><p class="mb-0 position-relative">Dosing</p></a>
                        <a href="../page36/index.html"><p class="mb-0 position-relative">Summary</p></a>
                        <a href="../page38/index.html"><p class="mb-0 position-relative">MM6 data</p></a>
                        <a></a>
                    </div>
                    <div class="footer_inner_nav1 position-static ms-auto bg-transparent p-0">
                        <ul class="justify-content-end">
                            <li>
                                <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                            </li>
                            <li>
                                <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                            </li>
                            <li>
                                <a href="../page27/index.html" class="text-uppercase">REF</a>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
    </div>

</body>

</html>